ITGB2-mediated drug carriers
Through the drug carrier designed by ITGB2 binding part, the problem of immunosuppression of M2 macrophages in solid cancer was solved, and the selective effect on M2 macrophages was achieved, which significantly improved the anti-cancer efficacy and reduced side effects. It is suitable for Prevention and treatment of various cancers.
Patent Information
- Application Number
- CN202380032965.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-07
- Filing Date
- 2023-04-06
- Publication Date
- 2024-11-15
AI Technical Summary
The existing anti-cancer treatment methods have low efficacy in solid cancer treatment, mainly because the microenvironment around the tumor inhibits immune function, especially M2 macrophages play an important role in promoting cancer growth and immunosuppression, and lack of targeting these cells. Effective targeted therapy.
Develop a drug vector containing an ITGB2 binding moiety that specifically binds to M2 tumor-associated macrophages, alleviates side effects and enhances anti-cancer efficacy, and induces cells through the binding of bee venom peptide or its variants to ITGB2. Apoptosis or other anti-cancer effects.
It has achieved selective effects on M2 macrophages, alleviated drug side effects, enhanced anti-cancer efficacy, and was effectively used for cancer prevention and treatment, especially in solid cancers, which significantly improved the therapeutic effect.
Smart Images

Figure CN118973601A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a drug carrier specifically binding to ITGB2. Background Art
[0002] Previous anticancer treatments were studied in the direction of directly attacking cancer cells or strengthening the activity of immune cells in the body that attack cancer cells. However, such anticancer agents also attack other normal cells other than cancer cells, have many side effects such as hair loss, nausea, and vomiting, and also cause additional reactions due to excessive increase of immune cells. Compared with previous chemotherapy or radiation therapy, an anticancer immunotherapy method that can minimize side effects is a method of using the immune system in the body to treat cancer. In such an anticancer immunotherapy method, a cell therapy method that directly injects into the body after activating T cells (including CAR-T), dendritic cells, natural killer cells, etc. as therapeutic immune cells in vitro, and a method for directly activating immune cells present in the body by injecting cancer antigens and immune activating substances into the body, thereby improving the anticancer efficacy of related anticancer vaccines, etc., are being actively carried out. However, such cell therapy agents or cancer vaccines are mainly used in diseases related to blood cancer, and have the disadvantage of very low therapeutic efficacy in most solid cancers. One of the reasons is that there are microenvironmental factors that inhibit immune function around solid cancers. In fact, in the tumor microenvironment, cells that reduce the function of immune cells (myeloid-derived stromal cells (MDSC), regulatory T cells (Treg), tumor-associated macrophages (TAM)) or immunosuppression-inducing cytokines, metabolites, etc.) actively act, thereby sharply reducing the activity of immune-activating substances and therapeutic immune cells. Therefore, the importance of developing therapeutic agents that have anti-cancer effects by regulating only the microenvironment around tumor cells without directly affecting tumor cells and immune cells to block the supply of nutrients to tumor cells and angiogenesis around tumor cells is becoming increasingly important. The tumor microenvironment plays a role in the proliferation and survival of malignant cells, angiogenesis, metastasis, abnormal adaptive immunity, and reduced response to hormones and chemotherapeutic agents, and is therefore considered a major therapeutic target.
[0003] The microenvironment surrounding the tumor is composed of endothelial cells, inflammatory cells, and fibroblasts. In the 1970s, it was found that tumor-associated macrophages (TAMs) play an important role in tumor growth. Tumor-associated macrophages play an important role by being associated with the overall tumor microenvironment such as cancer growth and metastasis. They are divided into two expression types: tumor suppressor M1 macrophages or tumor suppressor M2 macrophages. M1 macrophages have a strong ability to present antigens and are usually activated by interferon-γ, lipopolysaccharide (LPS), and tumor necrosis factor (TNF)-α, playing a pro-inflammatory and bactericidal role. M2 macrophages are known to promote immunosuppression, tumor formation, and angiogenesis by releasing a variety of extracellular matrix components, angiogenesis, and chemokines. Generally, they are induced by IL-4 and IL-13 and distinguished from M1 tumor-associated macrophages by expressing markers such as arginase-1, mannose (MMR, CD206), scavenger receptors (SR-A, CD204), CD163, and IL-10. Tumor-associated macrophages present around tumors are closely related to the growth and metastasis of tumor cells. It is reported that when a large number of M2 tumor-associated macrophages are present around tumors in cancer patients, the prognosis and survival rate of patients are poor. It is reported that M2 macrophages produce cytokines such as IL-10, TGFβ, and CCL18 that promote cancer growth, and receptors such as PDL1 and B7-1 / 2 present on the surface of M2 tumor-associated macrophages inhibit the anti-tumor activity of T cells and NK cells. In the microenvironment where a large number of M2 tumor-associated macrophages exist, tumor growth, differentiation, and metastasis are actively carried out. Therefore, it is necessary to develop targeted therapeutic agents targeting M2 tumor-associated macrophages. Summary of the invention
[0004] The purpose of the present invention is to provide a drug carrier targeting M2 macrophages.
[0005] Furthermore, an object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer.
[0006] Furthermore, an object of the present invention is to provide a method for screening a substance that specifically delivers a drug to M2 tumor-associated macrophages.
[0007] Another object of the present invention is to provide a method for screening patients responsive to an anticancer agent targeting M2 macrophages.
[0008] Furthermore, an object of the present invention is to provide a method for treating cancer.
[0009] At the same time, the object of the present invention is to provide a use of a drug carrier in preparing a pharmaceutical composition for preventing and treating cancer.
[0010] Technical Solution
[0011] In order to achieve the above object, the present invention provides a drug carrier, comprising an ITGB2 binding portion and a drug bound thereto.
[0012] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating cancer.
[0013] Furthermore, the present invention provides a method for screening a substance that specifically delivers a drug to M2 tumor-associated macrophages.
[0014] Furthermore, the present invention provides a method for screening a patient responsive to an anticancer agent targeting M2 macrophages.
[0015] Furthermore, the present invention provides a method for treating cancer, comprising the step of administering a pharmaceutically effective amount of the drug carrier of the present invention to an individual suffering from cancer.
[0016] At the same time, the present invention provides the use of the drug carrier of the present invention in preparing a pharmaceutical composition for preventing and treating cancer
[0017] Effects of the Invention
[0018] In the present invention, ITGB2 is confirmed to be a specific marker for cancer mediated by M2 macrophages. The drug carrier of the present invention comprising an ITGB2 binding portion that specifically binds to ITGB2 (integrin beta 2) selectively (or specifically) acts only on M2 tumor-associated macrophages, has the effect of reducing drug side effects and increasing drug efficacy, and can be effectively used as a drug carrier for apoptosis inducers, anticancer agents, contrast agents, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1a This figure shows the affinity of TAMpep for M2 macrophages confirmed by flow cytometry analysis.
[0020] Figure 1b This is a graph quantifying the affinity of TAMpep for M2 macrophages (*P<0.05 versus the M0 macrophages).
[0021] Figure 2a The figure shows the identification of proteins that bind to TAMpep in M2 macrophages by analyzing the Venn diagram of the M2 / M0 and M1 / M0 ratios.
[0022] Figure 2bThe diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M2 / M0 ratio.
[0023] Figure 2c The diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M1 / M0 ratio.
[0024] Figure 2d The diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M2 / M1 ratio.
[0025] Figure 3 The graph shows LC-MS chromatogram data obtained by reacting cell membrane proteins extracted from M0, M1, and M2 macrophages, respectively, with TAMpep826-biotin.
[0026] Figure 4 A diagram showing the identification of target proteins of TAMpep826 using LC-MS / MS proteomics.
[0027] Figure 5 It is a diagram showing the conditions of quantitative real-time polymerase chain reaction (Quantitative RT-PCR).
[0028] Figure 6 The figure shows the expression of ITGB2 messenger RNA (mRNA) in M2 macrophages.
[0029] Figure 7 The figure shows the confirmation of ITGB2 protein expression in M2 macrophages.
[0030] Figure 8 The figure shows the expression of ITGB2 protein in M2 macrophages confirmed by immunofluorescence analysis.
[0031] Fig. 9 The diagram shows the confirmation of ITGB2 expression in the cell membrane of M2 macrophages.
[0032] Fig.10 The diagram shows the interaction between TAMpep826 and ITGB2 confirmed in M2 macrophages by a pull-down assay.
[0033] Fig.11 The figure shows the confirmation of the interaction between TAMpep826 and ITGB2 in M2 macrophages by immunofluorescence analysis.
[0034] Fig.12 and Fig.13The figure shows the binding site of TB511 and ITGB2 confirmed by docking simulation.
[0035] Fig.14 Schematic diagram showing that the anti-CD18 antibody used in the preparation of the ITGB2-binding ADC of the present invention specifically binds to the active conformation (extended-open form) in the M2 TAM of CD18.
[0036] Fig.15 This is a picture obtained after ITGB2 was fixed on the surface of the sensor chip.
[0037] Fig.16 This is a diagram showing the binding ability of anti-ITGB2 antibodies to ITGB2 protein confirmed by surface plasmon resonance (SPR).
[0038] Fig.17 This is a diagram showing the binding ability between melittin-dKLA and ITGB2 protein confirmed by surface plasmon resonance.
[0039] Fig.18 A diagram showing the confirmation of ITGB2 mRNA expression in a cell model for ITGB2 expression inhibition established by Crispr / cas9 in M2 macrophages.
[0040] Fig.19 This figure confirms the apoptosis-reducing effect of melittin-dKLA in M2 macrophages by inhibiting ITGB2 expression.
[0041] Fig. 20 The graph confirms the apoptosis-inducing reducing effect of TB511 (TAMpep826-dKLA) in M2 macrophages by inhibiting ITGB2.
[0042] Fig.21 This figure confirms the apoptosis-inducing reducing effect of TB511 by the ITGB2 antibody in M2 macrophages.
[0043] Fig. 22 and Fig.23 The figure shows the confirmation of the effect of TB511 in breast cancer three-dimensional (3D) organoids.
[0044] Fig.24 and Fig.25 This figure shows the confirmation of the effect of TB511 in lung cancer three-dimensional organoids.
[0045] Fig.26 A diagram showing the confirmation of the effect of M-DM1 in lung cancer three-dimensional organoids.
[0046] Fig. 27 and Fig.28 The figure shows the confirmation of the effect of TB511 in three-dimensional organoids of lung cancer resistant to anticancer drugs.
[0047] Fig.29 and Fig.30 A diagram showing the effect of TB511 in three-dimensional organoids of prostate cancer resistant to anticancer drugs.
[0048] Fig.31 A diagram showing the confirmation of the effect of CD18-DM1 in breast cancer three-dimensional organoids.
[0049] Fig.32 A diagram confirming the effect of CD18-MMAE in breast cancer three-dimensional organoids.
[0050] Fig.33 and Fig.34 The diagram shows the confirmation of the effects of ADC (CD18-DM1 and CD18-MMAE) in lung cancer three-dimensional organoids.
[0051] Fig.35 and Fig.36 The diagram shows the confirmation of the effects of ADC (CD18-DM1 and CD18-MMAE) in three-dimensional organoids of lung cancer resistant to anticancer drugs.
[0052] Fig.37 and Fig.38 The figure shows the confirmation of the effect of ADC (CD18-DM1 and CD18-MMAE) in three-dimensional organoids of prostate cancer resistant to anticancer drugs. DETAILED DESCRIPTION
[0053] Best Mode for Carrying Out the Invention
[0054] Hereinafter, the present invention will be described in detail with reference to the accompanying drawings and by examples of the present invention. However, the following examples are only used to illustrate the present invention, and the present invention is not limited to these embodiments. When it is judged that the specific description of the technology or structure that is clear to the ordinary technicians in the technical field to which the present invention belongs may confuse the gist of the present invention, its detailed description will be omitted. The present invention can have various modifications and applications within the scope of the attached invention claims and the equivalent scope interpreted therefrom.
[0055] Furthermore, the terminology used in this specification is used to appropriately describe the preferred embodiments of the present invention, and may vary depending on the intention of the user, the operator, or the conventions of the technical field to which the present invention belongs. Therefore, these terms should be defined based on the full text of this specification. In the full text of the specification, when it is mentioned that a part "includes" a certain structural element, unless there is a special record to the contrary, it means that other structural elements may also be included, rather than excluding other structural elements.
[0056] Unless otherwise defined, all technical terms used in the present invention are used with the meanings commonly understood by those skilled in the art in the art to which the present invention belongs. In addition, although preferred methods or samples are described in this specification, similar or equivalent methods or samples are also included in the scope of the present invention. The contents of all publications described as references in this specification are integrated into the present invention.
[0057] Throughout this specification, not only single-letter or three-letter expressions of naturally occurring amino acids are used, but also three-letter expressions are used for other amino acids such as Aib (α-aminoisobutyric acid) and Sar (N-methylglycine). In addition, the amino acids expressed by abbreviations in the present invention are recorded according to the IUPAC-IUB nomenclature as follows.
[0058] Alanine: A, Arginine: R, Asparagine: N, Aspartic acid: D, Cysteine: C, Glutamic acid: E, Glutamine: Q, Glycine: G, Histidine: H, Isoleucine: I, Leucine: L, Lysine: K, Methionine: M, Phenylalanine: F, Proline: P, Serine: S, Threonine: T, Tryptophan: W, Tyrosine: Y and Valine: V.
[0059] In one embodiment, the present invention relates to a drug carrier comprising an ITGB2 binding moiety and a drug bound thereto.
[0060] In one example, ITGB2 may comprise the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8.
[0061] In one example, the ITGB2 binding portion can specifically bind to the ITGB2 protein present in the cell membrane of M2 tumor-associated macrophages, and can include small molecules, viruses, antibodies, antibody fragments, nucleic acid aptamers, hormones, cytokines, chemokines, ligands, peptides that are part of the region of cytokines, or peptides that are part of the region of ligands that specifically bind to ITGB2.
[0062] In one example, the binding moiety may also include a targeting sequence, tag, labeled residue or amino acid sequence designed for a specific purpose such as increasing half-life or stability.
[0063] In one embodiment, the ITGB2 binding portion can bind to the extended active conformation of CD18.
[0064] In one example, the ITGB2 binding moiety can bind to amino acids 449 to 617 of ITGB2.
[0065] In one example, the ITGB2 binding portion can bind to amino acids 466 to 565 of ITGB2.
[0066] In one example, the ITGB2 binding portion may comprise melittin, a variant thereof or an analog thereof, and may comprise the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
[0067] In one example, the drug carrier may include one or more selected from the group consisting of amino acid sequences of SEQ ID NO: 3 to SEQ ID NO: 6.
[0068] In one example, the drug carrier can be a peptide-drug conjugate (PDC), can be bee venom peptide-dKLA comprising the amino acid sequence of sequence 5, can be TB511 comprising the amino acid sequence of sequence 6, or can be M-DM1 in which maleimide-modified bee venom peptide is connected to the drug DM1.
[0069] In one example, TB511 can bind to amino acids 466 to 565 of ITGB2, LEU (6) of TB511 can bind to LEU (528), THR (538), LEU (556), CYS (557) and PHE (558) sites of ITGB2, and TRP (12) of TB511 can bind to GLU (466), ILE (469), CYS (470) and ARG (471) of ITGB2.
[0070] In one example, the above-mentioned ITGB2 binding portion can bind to an epitope of ITGB2 (CD18) comprising amino acids 732 to 748 (SEQ ID NO: 9), an epitope comprising amino acids 504 to 508, an epitope comprising amino acids 534 to 546, an epitope comprising amino acids 449 to 617, or an epitope comprising amino acids 23 to 700 (Gln23-Asn700).
[0071] In one example, the ITGB2 binding portion may be an antibody that binds to the epitope or an immunologically active fragment thereof.
[0072] In one embodiment, the above-mentioned fragment having immunological activity can be selected from Fab, Fd, Fab', dAb, F(ab'), F(ab') 2 , scFv (single chain fragment variable), Fv, single chain antibody, Fv dimer, complementarity determining region fragment, humanized antibody, chimeric antibody and bispecific antibody (diabody) One or more of the group consisting of.
[0073] In one example, the drug carrier can be an antibody-drug conjugate (ADC).
[0074] In one example, the ITGB2 binding portion of the drug carrier and the drug can be covalently bound via a linker or non-covalently bound without a linker.
[0075] In one example, the ITGB2 binding portion of the drug carrier can be connected / bound to the drug through a linker, and the linker can be a peptide or any linker having a functional group that can be bound through an amine group, a carboxyl group, or a sulfhydryl group of a protein such as a ligand, an antibody, or an antibody fragment, or a phosphate group or a hydroxyl group of a nucleic acid such as a nucleic acid aptamer.
[0076] In one example, the linker can be selected appropriately according to the drug. For example, the drug can be linked to a linker having an aldehyde functional group and then be bound to the amino group at the N-terminus of the antibody (cell targeting region) of the ITGB2 binding part as a drug carrier.
[0077] The functional group of the linker can be isothiocyanate, isocyanates, acyl azide, NHS ester, sulfonyl chloride, aldehyde, glyoxal, epoxide, oxirane, carbonate, arylhalide, imidoester, carbodiimide, anhydride, fluorophenyl ester, hydroxymethyl phosphine, maleimide, haloacetyl, pyridyldisulfide, thiosulfonate or vinylsulfone. The linker may be a linker that can be cleaved by a protease, or can be cleaved under acidic or alkaline conditions, or can be cleaved by high temperature or light irradiation, or can be cleaved under reducing or oxidizing conditions, or may be a linker that is not cleavable under the above conditions. The cleavable linker can be, for example, a hydrazone linker that is cleaved under acidic conditions, a peptide linker that is cleaved by a protease, a linker having a disulfide functional group that is cleaved under reducing conditions, and the non-cleavable linker can be an MCC (maleimidomethylcyclohexane-1-carboxylate) linker, an MC (maleimidocaproyl) linker, or a succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sMCC) linker or a sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-sMCC) linker as a derivative thereof.
[0078] Furthermore, the linker may be a self-immolative linker or a traceless linker that leaves no trace after cleavage. The self-destructive linker can be, for example, the linker disclosed in U.S. Patent No. 9,089,614, entitled “Hydrophilic self-immolative linkers and conjugates thereof”, the linker disclosed in International Publication No. WO2015038426, entitled “SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACIDDERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF”, and the linker that leaves no trace after cleavage can be a phenylhydrazide linker, an aryl-triazene linker, a linker disclosed in the document [Blaney, et al., “Traceless solid-phase organic synthesis,” Chem Rev. 102: 2607-2024 (2002)], etc.
[0079] In the technical field to which the present invention belongs, in addition to the linkers exemplified above, many linkers that can be used in the present invention are known through a considerable number of documents. For the above literature, please refer to the literature [Castaneda, et al, "Acid-cleavable thiomaleamic acid linker for homogeneous antibody drug conjugation," Chem Commun. 49:8187-8189 (2013)], the literature [Lyon, et al, "Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates," Nat Biotechnol.32(10):1059-1062(2014)], literature[Dawson,et al"Synthesis of proteins by native chemical ligation,"Science1994,266,776-779], literature[Dawson,et al"Modulation of Reactivity in Native Chemical Ligationthrough the Use of Thiol Additives,"J Am Chem Soc.1997,119,4325-4329], Document [Hackeng, et al "Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology," Proc Natl Acad Sci USA 1999, 96, 10068-10073], Document [Wu, et al "Building complex glycopeptides: Development of acysteine-free native chemical ligation protocol," Angew Chem Int Ed 2006, 45, 4116-4125], literature [Geiser et al "Automation of solid-phase peptide synthesis" in Macromolecular Sequencing and Synthesis, Alan R Liss, Inc, 1988, pp 199-218], literature [Fields, G and Noble, R (1990) " Solid phase peptide synthesis utilizing 9-fluoroenylmethoxycarbonyl amino acids",Int J Peptide Protein Res 35:161-214], etc., or refer to U.S. Patent No. 6884869, U.S. Patent No. 7498298, U.S. Patent No. 8288352, U.S. Patent No. 8609105, U.S. Patent No. 8697688, U.S. Patent Publication No. 2014 / 0127239, U.S. Patent Publication No. 2013 / 028919, U.S. Patent Publication No. 2014 / 286970, U.S. Patent No. Publication No. 2013 / 0309256, U.S. Patent Publication No. 2015 / 037360, U.S. Patent Publication No. 2014 / 0294851, International Patent Publication WO2015057699, International Patent Publication WO2014080251, International Patent Publication WO2014197854, International Patent Publication WO2014145090, International Patent Publication WO2014177042, etc. .
[0080] The ITGB2 binding part of the drug carrier of the present invention can also bind to the drug through the mediation of a biocompatible polymer or by using the biocompatible polymer as a carrier. A biocompatible polymer refers to a polymer having tissue compatibility and anticoagulant properties that do not cause tissue necrosis or blood coagulation by being compatible with biological tissues or blood.
[0081] The synthetic polymer as the above-mentioned biocompatible polymer is polyester, polyhydroxyalkanoate (PHAs), poly(α-hydroxy acid), poly(β-hydroxy acid), poly(3-hydroxybutyric acid-valeric acid) (PHBV), poly(3-hydroxypropionate) (PHP), poly(3-hydroxyhexanoate) (PHH), poly(4-hydroxy acid), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(esteramide), polycaprolactone, polylactide, polyglycolide, poly(lactide-co-glycolide) (PLGA), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid-co-trimethylene carbonate), polyphosphate, polyphosphate ester polyurethane, poly(amino acid), polycyanoacrylate, poly(trimethylene carbonate), poly(imino carbonate), poly(tyrosine carbonate), polycarbonate, poly(tyrosine arylate), polyalkylene oxalate, polyphosphocyanate, PHA-P EG, ethylene-vinyl alcohol copolymer (EVOH), polyurethane, silicone, polyether, polyolefin, polyisobutylene and ethylene-α-olefin copolymer, styrene-isobutylene-styrene triblock copolymer, acrylic polymer copolymer, vinyl halide polymer and copolymer, polyvinyl chloride, polyvinyl ether, polyvinyl methyl ether, polyvinylidene halide, polyvinylidene fluoride, polyvinylidene chloride, polyfluoroolefin, polyperfluoroolefin, polyacrylonitrile, polyvinyl ketone, polyvinyl aromatic compound, polystyrene, polyvinyl ester, polyvinyl acetate, ethylene-methyl methacrylate copolymer, acrylonitrile-styrene copolymer, ABS resin and ethylene-vinyl acetate copolymer, polyamide, alkyd resin, polyoxymethylene, polyimide, polyether, polyacrylate, polymethacrylate, polyacrylic acid-co-maleic acid and polyaminoamine, natural polymer is chitosan, dextran, cellulose, heparin, hyaluronic acid, alginate, inulin, starch or glycogen.
[0082] The linker used in the binding of the ITGB2 binding moiety to the drug is stable outside the target cell and is not cleaved, and preferably is a linker that is not cleaved even in the endosome or ribosome under acidic conditions in the target cell. The linker is stable outside the target cell and is not cleaved, thereby allowing the drug to move into the cell, and is not cleaved in the endosome or ribosome under acidic conditions, thereby allowing the drug to move from the endosome or ribosome to the cytoplasm.
[0083] In the drug carrier of the present invention, the drug can also bind to the ITGB2 binding part by non-covalent bonds. For example, intercalators such as doxorubicin, which is a kind of anticancer agent that exerts its effect by intercalation of nucleic acids, can be bound by non-covalent insertion of nucleic acid aptamers when using nucleic acid aptamers as the cell targeting region of the drug carrier. Nucleic acid aptamers are oligonucleotide molecules, and therefore have base stacking of nucleotide bases, and drugs can be bound between base stacking by intercalation.
[0084] In one example, the ITGB2 binding portion can also be conjugated to RNA, DNA, antibodies, effectors, drugs, prodrugs, toxins, peptides or delivery molecules (see Shoari et al., Pharmaceutics 13:1391, pp.1-32 (2021)).
[0085] In the drug carrier of the present invention, the drug is not particularly limited as long as it can move into the cell to exert its effect. The above-mentioned drug can be a drug formed by any low molecular weight compound such as a cytotoxic anticancer agent, a recombinant protein, an siRNA, and any other biological drug. In addition, at the efficacy level, the drug can be an anti-inflammatory agent, an analgesic, an anti-arthritic agent, an antispasmodic agent, an antidepressant, an antipsychotic drug, a neurostabilizer, an anxiolytic, an anesthetic antagonist, an anti-Parkinson's disease drug, a cholinergic agonist, an anticancer agent, an angiogenesis inhibitor, an immunosuppressant, an immune promoter, an antiviral agent, an antibiotic, an appetite suppressant, an analgesic, an anticholinergic, an antihistamine, an anti-migraine agent, a hormone agent, a coronary artery, a vasodilator, a contraceptive, an antithrombotic agent, a diuretic, an antihypertensive agent, a cardiovascular disease therapeutic agent, a contrast agent, and other diagnostic agents.
[0086] In one example, the drug can be a compound, RNA, DNA, antibody, effector, prodrug, toxin, peptide or radionuclide.
[0087] In one example, the drug can be an immunogenic apoptosis inducer, a pro-apoptotic peptide, a microtubulin structure formation inhibitor, a meiosis inhibitor, a topoisomerase inhibitor, a DNA intercalator, a toxin or an anticancer agent.
[0088] In one example, the pro-apoptotic peptide can be selected from the group consisting of KLA, alpha-defensin-1, BMAP-28, Brevenin-2R, Buforin IIb, cecropin A-Magainin 2 (CA-MA-2), cecropin A, cecropin B, chrysophsin-1, D-K6L9, Gomesin, Lactoferricin B, LLL27, LTX-315, Magainin2, Magainin II-bombesin conjugate (MG2B), Pardaxin and a combination thereof.
[0089] In one example, the above-mentioned immunogenic apoptosis inducer can be selected from the group consisting of anthracycline anticancer agents, taxane anticancer agents, anti-EGFR antibodies, BK channel agonists, bortezomib, cardiac glycosides, cyclophosphamide anticancer agents, GADD34 / PP1 inhibitors, LV-tSMAC, measles virus, bleomycin, mitoxantrone, oxaliplatin and combinations thereof.
[0090] In one embodiment, the anticancer agent can be selected from 7-ethyl-10-hydroxycamptothecin (SN-38, 7-Ethyl-10-hydroxy-camptothecin), daunorubicin, doxorubicin, epirubicin, idarubicin, pixantrone, sabarubicin, valrubicin, paclitaxel, docetaxel, mechloethamine, phenoxyacetylcholine, chloramphenicol ... Chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, dactinomycin (actinomycin D), plicamycin, mitomycin C, vincristine, vinblastine, teniposide, topotecan, irinotecan, uramustine, melphalan, bendamustine, dacarbazine, temozolomide, altretamine, duocarmycin, nedaplatin, oxaliplatin, satraplatin, triplatin tetranitratetetranitrate), 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cystarbine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed The invention can be selected from the group consisting of metrexed, pentostatin, thioguanine, etoposide, mitoxantrone, izabepilone, vindesine sulfate, vinorelbine, estramustine, maytansine, DM1 (mertansine), DM4, dolastatin, auristatin E, auristatin F, monomethyl auristatin E (MMAE), monomethyl auristatin F and their derivatives, which can be DM1 or MMAE.
[0091] In the present invention, preferably, the drug is a cytotoxic anticancer agent. Cytotoxic anticancer agents can be generally divided into metabolic antagonists (Antimetabolites), tubulin targeting agents (tubulin polymerase inhibitors and tubulin depolymerisation), alkylating agents, mitotic inhibitors (Antimitotic Agents), DNA cleavage agents, DNA cross-linker agents, DNA intercalators, DNA topoisomerase inhibitors, etc., and the well-known metabolic antagonists in the technical field of the present invention include methotrexate and folic acid (Folic acid) The following are some of the most common anti-cancer drugs: oxaliplatin, oxaliplatin, pyrimidine, dapoxetine ... In addition, the mitotic inhibitors known in the technical field of the present invention include taxane preparations such as docetaxel and paclitaxel, Vinca alkalids such as vinflunine, podophyllotoxin derivatives such as etoposide, etc., DNA cleaving agents include calicheamicins, etc., and DNA cross-linking agents include PBD dimers, etc. In addition, the DNA intercalating agents known in the technical field of the present invention include doxorubicin, etc., and DNA topoisomerase inhibitors include SN-28, etc.
[0092] Furthermore, the drug may be a gene, plasmid DNA, antisense oligonucleotide, siRNA, peptide, ribozyme, viral particle, immunomodulator, protein, contrast agent, etc. More specifically, the drug may be a gene encoding Rb94, which is a variant of the retinoblastoma tumor suppressor gene, a gene encoding apoptin, which induces apoptosis only in tumors, an antisense oligonucleotide (sequence: 5'-TCC ATG GTG CTC ACT-3') for HER-2, which is a therapeutic target, or a diagnostic contrast agent such as Gd-DTPA, which is an MRI contrast agent.
[0093] The complex of the drug carrier and the drug of the present invention may include a pharmaceutical composition prepared as an oral dosage form or a parenteral dosage form by a pharmaceutically acceptable carrier according to the usual method in the technical field of the present invention according to the route of administration. Among them, "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not stimulate the organism and does not reduce the biological activity and characteristics of the administered compound. In the composition prepared as a liquid solution, the pharmaceutically acceptable carrier can be sterilized and suitable for the organism. Saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, glucose solution, maltodextrin solution, glycerol, ethanol and a mixture of these components are used. Other common additives such as antioxidants, buffers, antimicrobial agents, etc. can also be added as needed.
[0094] In one example, the drug carrier of the present invention can specifically deliver the above-mentioned drug to M2 tumor-associated macrophages.
[0095] In the present invention, the ITGB2 binding portion enables selective binding by binding to ITGB2 of M2 tumor-associated macrophages as target cells, thereby providing a targeting function. The ITGB2 binding portion induces endocytosis by specifically binding to ITGB2 present on the surface of target cells, thereby enabling the movement of the drug bound thereto into the cell.
[0096] In the present invention, antibodies, nucleic acid aptamers, hormones (e.g., erythropoietin hormone) that are secreted in specific cells and act on surface receptors of other cells that are target cells to play a role in intercellular signaling, cytokines or chemokines (e.g., IL13), ligands of biomolecules such as VEGF (vascular endothelial growth factor) and BDNF (brain-derived neurotrophic factor) that bind to surface receptors of target cells, and peptides that are partial regions of these factors that show the ability to specifically bind to receptors can be used as ITGB2 binding moieties. Typically, antibodies or nucleic acid aptamers can be used. The antibody as the ITGB2 binding portion may be not only a monoclonal antibody or a polyclonal antibody, but also a multispecific antibody (i.e., a bispecific antibody that recognizes two or more antigens or two or more epitopes, etc.), or an antibody fragment that can show the ability to specifically bind to ITGB2, a chemically modified antibody, a chimeric antibody (human-mouse chimeric antibody, human-monkey chimeric antibody, etc.), a humanized antibody or a human antibody with reduced immunogenicity, etc. In addition, various forms of antibody fragments and chemically modified antibodies are also well known in the technical field to which the present invention belongs, for example, Fab, Fd, Fab', dAb, F(ab'), F(ab') 2 , scFv, Fv, single-chain antibody, Fv dimer, complementary determining region fragment, humanized antibody, chimeric antibody and bispecific antibody, etc., or it can be an antibody fragment obtained by treating the antibody with a protease, for example, papain or pepsin.
[0097] Regarding methods for preparing antibodies, antibodies that increase specificity for target antigens or improve immunogenicity by artificially deforming natural antibodies, etc., reference can be made to various documents known in the technical field to which the present invention belongs, such as U.S. Pat. No. 4,444,887, U.S. Pat. No. 4,716,111, U.S. Pat. No. 5,545,806, U.S. Pat. No. 5,814,318, International Publication No. WO 98 / 46645, International Publication No. WO 98 / 50433, International Publication No. WO 98 / 24893, International Publication No. WO 98 / 16654, International Publication No. WO 96 / 34096, International Publication No. WO 96 / 33735, document [Protein Eng 1994, 7(6):805-814], document [Proc Natl Acad Sci USA 1994, 91:969-973], etc.
[0098] The nucleic acid aptamer used as the cell targeting region can be a single-stranded DNA nucleic acid aptamer or a single-stranded RNA nucleic acid aptamer. Similar to antibodies, nucleic acid aptamers refer to nucleic acid ligands that can specifically bind to target molecules such as target antigens. If they can specifically bind to target molecules, nucleic acid aptamers can also be double-stranded DNA or RNA nucleic acid aptamers. The preparation and screening methods of the above-mentioned nucleic acid aptamers that can specifically bind to target molecules are well known in the technical field to which the present invention belongs. In the specific methods for screening nucleic acid aptamers or the use of appropriate reagents, materials, etc., reference can be made to the literature [Methods Enzymol 267:275-301, 1996], the literature [Methods Enzymol 318:193-214, 2000], etc. In order to increase the half-life, nucleic acid aptamers can be nucleic acid aptamers that are deformed in sugars, phosphates and / or bases. In the technical field to which the present invention belongs, the specific contents of the nucleic acids deformed in the above-mentioned sugars, phosphates and / or bases, including the preparation method, are well known. For example, a sugar-modified nucleotide may be a nucleotide in which the hydroxyl group (OH group) of the sugar is modified by a halogen group, an aliphatic group, an ether group, an amine group, etc., and may be a nucleic acid in which the ribose or deoxyribose itself as a sugar is substituted by a sugar analogue capable of replacing them, such as α-anomeric sugars, arabinose, xyloses, or lyxoses, epimeric sugars, pyranose sugars, furanose sugars, etc. Also, for example, a phosphate modification may be a nucleic acid in which the phosphate is modified to P(O)S (thioate), P(S)S (dithioate), P(O)NR2 (amidate), P(O)R, P(O)OR', CO or CH2 (formacetal), etc. The above R or R' is H or a substituted or unsubstituted alkyl group, etc., and when deformed in phosphoric acid, the linking group is -O-, -N-, -S- or -C-, and adjacent nucleic acids are bound to each other through these linking groups.
[0099] The drug carrier of the present invention directly and specifically binds to ITGB2 expressed on the cell membrane of M2 tumor-associated macrophages, especially to ITGB2 (CD18) in the active conformation in M2TAM, so that drugs that non-selectively show drug effects can selectively show drug effects only on M2 tumor-associated macrophages that express and serve as ITGB2 as a target molecule and are activated without side effects.
[0100] In one embodiment, the present invention relates to a peptide-drug conjugate comprising an ITGB2 binding moiety comprising melittin, a variant thereof or an analog thereof and a drug conjugated thereto.
[0101] In one example, the above-mentioned PDC can bind to amino acids 466 to 565 of ITGB2, and can bind to LEU (528), THR (538), LEU (556), CYS (557), PHE (558), GLU (466), ILE (469), CYS (470) or ARG (471) of ITGB2.
[0102] In one example, the PDC may be melittin-dKLA comprising the amino acid sequence of sequence 5, may be TB511 comprising the amino acid sequence of sequence 6, or may be M-DM1 in which maleimide-modified melittin is linked to drug DM1.
[0103] In one example, TB511 can bind to amino acids 466 to 565 of ITGB2, LEU (6) of TB511 can bind to LEU (528), THR (538), LEU (556), CYS (557) and PHE (558) sites of ITGB2, and TRP (12) of TB511 can bind to GLU (466), ILE (469), CYS (470) and ARG (471) of ITGB2.
[0104] In one embodiment, the present invention relates to an antibody-drug conjugate comprising an antibody or an immunologically active fragment thereof that binds to ITGB2 and a drug bound thereto.
[0105] In one example, the ADC may bind to an epitope of ITGB2 comprising amino acids 732 to 748, an epitope comprising amino acids 504 to 508, an epitope comprising amino acids 534 to 546, an epitope comprising amino acids 449 to 617, or an epitope comprising amino acids 23 to 700.
[0106] In one example, the ADC may further comprise an antibody-drug conjugate linker, and the ADC linker may be 6-maleimidocaproyl (MC), maleimidopropionyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), valine-citrulline-p-aminobenzyloxycarbonyl (val-cit-PAB) or N-succinimidyl (4-iodoacetyl) aminobenzoate (SIAB).
[0107] In one example, the above antibody-drug conjugate can form a complex between the anti-CD18 antibody or its immunologically active fragment and the drug through an ADC linker.
[0108] The above antibodies are not only in the form of complete antibodies, but also include functional fragments of antibody molecules. A complete antibody has a structure with two full-length light chains and two full-length heavy chains, and each light chain is bound to a heavy chain by a disulfide bond. The functional fragment of an antibody molecule refers to a fragment that retains the antigen binding function. Examples of antibody fragments include: (i) a Fab fragment composed of the variable region (VL) of the light chain and the variable region (VH) of the heavy chain, as well as the constant region (CL) of the light chain and the first constant region (CH1) of the heavy chain; (ii) a Fd fragment composed of the VH and CH1 domains; (iii) an Fv fragment composed of the VL and VH domains of a single antibody; (iv) a dAb fragment composed of the VH domain (Ward ES et al., Nature 341:544-546 (1989)]; (v) an isolated CDR region; (vi) a F(ab') fragment that is a bivalent fragment comprising two connected Fab fragments. 2 fragments; (vii) single-chain Fv molecules (scFv) that form an antigen-binding site by binding the VH domain to the VL domain through a peptide linker; (viii) bispecific single-chain Fv dimers (PCT / US92 / 09965); and (ix) bispecific antibodies prepared as multivalent or multispecific fragments by gene fusion (WO94 / 13804), etc.
[0109] The antibody or immunologically active fragment thereof of the present invention can be selected from the group consisting of animal-derived antibodies, chimeric antibodies, humanized antibodies, human antibodies and immunologically active fragments thereof. The above-mentioned antibody can be produced by recombination or synthesis.
[0110] Animal-derived antibodies produced by immunizing animals with desired antigens usually cause immune rejection when administered to humans for therapeutic purposes. Chimeric antibodies have been developed to suppress such immune rejection. Chimeric antibodies use genetic engineering methods to replace the constant region of animal-derived antibodies that are the cause of anti-isotype reactions with the constant region of human antibodies. Compared with animal-derived antibodies, chimeric antibodies improve a considerable part of anti-isotype reactions, but still contain potential side effects related to anti-idiotypic reactions due to the presence of animal-derived amino acids in the variable region. Humanized antibodies have been developed to improve such side effects. They are prepared by transplanting the complementary determining regions (CDRs) in the variable region of chimeric antibodies, which play an important role in antigen binding, into the human antibody framework.
[0111] In the CDR grafting technology for preparing humanized antibodies, it is very important to select the most optimized human antibody that can best accept the CDR site of the animal-derived antibody, and for this purpose, antibody databases, crystal structure analysis, molecular modeling technology, etc. are used. However, even if the CDR site of the animal-derived antibody is grafted to the optimized human antibody framework, there are still amino acids located in the framework of the animal-derived antibody that affect antigen binding, and in many cases, the antigen binding ability cannot be preserved. Therefore, the application of additional antibody engineering technology to restore the antigen binding ability can be said to be necessary.
[0112] The above-mentioned antibody or fragment thereof having immunological activity may be isolated from an organism (not present in an organism) or non-naturally produced (non-naturally occurring), for example, may be produced synthetically or recombinantly.
[0113] In the present invention, "antibody" refers to a substance generated by the stimulation of an antigen in the immune system, and its type is not particularly limited and can be obtained by natural or non-natural (e.g., synthetic or recombinant) methods. Not only in vitro, antibodies are also very stable and have a long half-life in vivo, so they are conducive to mass expression and production. In addition, the antibody itself has a dimer structure, so the affinity is very high. A complete antibody is a structure with only two full-length light chains and two full-length heavy chains, and each light chain is connected to the heavy chain by a disulfide bond. The constant region of an antibody is divided into a heavy chain constant region and a light chain constant region, and the heavy chain constant region has gamma (γ), muon (μ), alpha (α), delta (δ) and ipsilon (ε) types, and subtypes are gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1) and alpha 2 (α2). The constant region of the light chain has kappa (κ) and lambda (λ) types.
[0114] The term "heavy chain" in the present invention is interpreted as a variable region domain V containing an amino acid sequence having a sufficient variable region sequence in order to confer specificity to an antigen. H and contains three constant region domains C H1 , C H2 , C H3 The term "light chain" refers to a variable region domain V having an amino acid sequence with sufficient variable region sequence to confer specificity to an antigen. L and containing constant region domain C L The meaning of the full-length light chain and its fragments.
[0115] The term "variable region" or "variable site" in the present invention refers to a portion of an antibody molecule that shows many variations in sequence while performing the function of specifically binding to an antigen, and the variable region contains CDR1, CDR2, and CDR3 as complementary determining regions. A framework region (FR) portion exists between the above CDRs to support the CDR loop. The above "complementarity determining region" is a loop-shaped site associated with antigen recognition, and the specificity of an antibody to an antigen is determined by changes in the sequence of this site.
[0116] The term "single chain variable region fragment (scFv, single chain fragment variable)" used in the present invention refers to a single-chain antibody prepared by expressing only the variable region of an antibody through genetic recombination, and refers to an antibody in a single-chain form in which the VH region and the VL region of the antibody are connected by a short peptide chain. If there is no other explicit indication or no other understanding from the context, the above term "scFv" means the scFv fragment including the antigen binding fragment. This is self-evident to a person skilled in the art of the present invention.
[0117] The term "complementarity determining region (CDR)" in the present invention refers to the amino acid sequence of the hypervariable region of the heavy chain and light chain of an immunoglobulin. The heavy chain and the light chain may each contain three CDRs (CDRH1, CDRH2, CDRH3 and CDRL1, CDRL2, CDRL3). The above CDRs may provide the main contact residues when the antibody binds to the antigen or antigenic determinant.
[0118] In the present invention, the term "specific binding" or "specific recognition" has the same meaning as commonly known to those skilled in the art, and refers to the specific interaction between antigen and antibody to induce an immune response.
[0119] The term "antigen-binding fragment" in the present invention refers to a fragment of the entire immunoglobulin structure, and refers to a portion of a polypeptide that includes a portion that can bind to an antigen. For example, it can be scFv, (scFv)2, scFv-Fc, Fab, Fab' or F(ab') 2 In the above antigen-binding fragment, Fab may have a variable region of a light chain and a heavy chain, a constant region of a light chain, and a first constant region of a heavy chain (C H1 ) structure to have an antigen binding site. The difference between Fab' and Fab is that in the heavy chain C H1 The C-terminus of the domain has a hinge region containing one or more cysteine residues. 2Antibodies are generated by forming disulfide bonds between the cysteines in the hinge region of Fab'. Fv is the smallest antibody fragment having only the heavy chain variable region and the light chain variable site, and the recombinant technology for generating Fv fragments is well known in the technical field to which the present invention belongs. Double-chain Fv (two-chain Fv) connects the heavy chain variable site and the light chain variable site by non-covalent bonds, and single-chain Fv (single-chain Fv) usually connects the heavy chain variable region and the light chain variable region by covalent bonds through a peptide linker or directly connects them at the C-terminus, and can form a dimer structure like a double-chain Fv. The above-mentioned linker can be a peptide linker formed by 1 to 100 or 2 to 50 arbitrary amino acids, and appropriate sequences are known in the technical field to which the present invention belongs. The above-mentioned antigen-binding fragment can be obtained by using a proteolytic enzyme (for example, Fab can be obtained by limited cleavage of a full-length antibody using papain, and F(ab') can be obtained by cleavage using pepsin) 2 fragment), can be prepared by genetic recombination technology.
[0120] The term "hinge region" in the present invention refers to a region contained in the heavy chain of an antibody and exists between the C H1 With C H2 The region between the regions refers to a region that provides flexibility to the antigen-binding site in the antibody. For example, the hinge may be derived from a human antibody, specifically, from IgA, IgE or IgG, for example, from IgG1, IgG2, IgG3 or IgG4.
[0121] The antibody of the present invention or its immunologically active fragment can be prepared by any method known in the art to which the present invention belongs. After encoding the polypeptide sequence of the antibody of the present invention or its immunologically active fragment, if necessary, it is cloned into a host cell and used in the formation of nucleic acid for expression and identification. Various methods for this purpose are described in the literature (Molecular Cloning-A Laboratory Manual, 3rd Ed., Maniatis, Cold Spring Harbor Laboratory Press, New York, 2001; Current Protocols in Molecular Biology, John Wiley & Sons).
[0122] The nucleic acid encoding the antibody of the present invention or its immunologically active fragment can be inserted into an expression vector for expressing protein. The expression vector usually contains a regulatory or control sequence, a screening marker, an arbitrary fusion ligand and / or an additional element in an operably connected manner, that is, a protein that improves the functional relationship. Under appropriate conditions, the antibody of the present invention or its immunologically active fragment can be produced by culturing a host cell transformed by nucleic acid, preferably, by culturing an expression vector containing a nucleic acid encoding the antibody of the present invention or its immunologically active fragment to induce protein expression. A variety of appropriate host cells including mammalian cells, viruses, insect cells and yeast can be used, but are not limited thereto. The method of introducing exogenous nucleic acids into host cells is well known in the technical field to which the present invention belongs, and varies with the host cells used. Preferably, Escherichia coli with low production cost and high industrial utilization value is used as a host cell to produce the antibody of the present invention or its immunologically active fragment.
[0123] In one embodiment, the present invention relates to a chimeric antigen receptor (CAR) comprising the antibody or an immunologically active fragment thereof that binds to ITGB2 of the present invention as an antigen binding domain.
[0124] In one embodiment, the present invention relates to a recombinant vector comprising a gene encoding the above-mentioned chimeric antigen receptor.
[0125] In one embodiment, the present invention relates to a chimeric antigen receptor-expressing cell transformed with the above-mentioned recombinant vector.
[0126] In one example, the chimeric antigen receptor expressing cell can be a chimeric antigen receptor expressing macrophage (CAR-macrophage), a chimeric antigen receptor expressing T (CAR-T) cell, a chimeric antigen receptor expressing γ-δT (CAR-Gamma-delta T) cell or a natural killer (CAR-NK) cell.
[0127] The term "chimeric antigen receptor (CAR)" in the present invention refers to a non-natural receptor that can confer specificity to a specific antigen on immune effector cells. Typically, the above-mentioned CAR refers to a receptor used to transplant the specificity of monoclonal antibodies to T cells. CAR is generally composed of an extracellular domain (Ectodomain), a transmembrane domain (transmembrane domain) and an intracellular domain (Ectodomain).
[0128] The extracellular domain includes an antigen binding site (antigen recognition region), and the transmembrane domain of CAR is a form connected to the extracellular domain, which can be derived from nature or synthesis. In the case of being derived from nature, it can be derived from membrane-bound or transmembrane proteins, and can be derived from the α, β or ζ chain of the T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CDS, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154 or CD8 and other proteins. The sequence of the transmembrane domain can be obtained by the known literature in the technical field of the present invention of the transmembrane region of the known transmembrane protein, but is not limited thereto.
[0129] Furthermore, when the transmembrane domain is synthetically derived, it may mainly contain hydrophobic amino acid residues such as leucine and valine. For example, there is a transmembrane domain synthesized from a triplet of phenylalanine, tryptophan and valine, but the present invention is not limited thereto. Sequence information about the transmembrane domain can be obtained from publicly known documents in the technical field of the present invention related to synthetic transmembrane domains, but the present invention is not limited thereto.
[0130] In the CAR of the present invention, the intracellular domain is a part of the domain of the CAR present in the cell, and is a form connected to the transmembrane domain. The intracellular domain of the present invention may include a feature of activating T cells when the antigen binding site of the CAR binds to the antigen, preferably, an intracellular signaling domain having the feature of bringing about T cell proliferation. As long as the intracellular signaling domain is a part that can bring about a signal to activate T cells when the antibody binds to the antigen binding site present outside the cell, its type is not particularly limited, and a variety of intracellular signaling domains can be used, for example, it can be an immune receptor based on tyrosine activation motif (tyrosine-based activation motif) or ITAM, and the ITAM may include CD3 Zeta (ξ, zeta), FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CDS, CD22, CD79a, CD79b, CD66d or FcεRIγ, but is not limited thereto.
[0131] CAR contains a single-chain fragment variable region (scFv) of a tumor-associated antigen (TAA)-specific antibody coupled by a hinge and a transmembrane region in the cytoplasmic domain of a T cell signaling molecule. Most common lymphocyte activation motifs contain T cell co-stimulatory (e.g., CD28, CD137, OX40, ICOS, and CD27) domains in a tandem with a T cell trigger (e.g., CD3ζ) motif. CAR-mediated adoptive immunotherapy is a method for directly recognizing TAAs on target tumor cells in a non-HLA restricted manner for cells transplanted with CAR.
[0132] The term "chimeric antigen receptor expressing T (CAR-T) cells" in the present invention refers to T cells expressing CAR. The above-mentioned chimeric antigen receptor expressing T cells have the following advantages: ⅰ) sensing cancer antigens in a manner independent of human leukocyte antigen (HLA, humanleukocyte antigen), can treat cancers that evade the effects of anticancer agents by reducing the expression of HLA on the cell surface; ⅱ) since it is independent of the HLA type, it can be used in treatment regardless of the patient's HLA type; ⅲ) a large number of cancer-specific T cells can be generated in a short time, thereby showing excellent anti-cancer effects.
[0133] These T cells have CD4 + T cells (helper T cells, TH cells), CD8 + T cells (cytotoxic T cells, CTL), memory T cells, regulatory T cells (Treg cells), natural killer T cells, etc. Preferably, the T cells introduced with CAR in the present invention are CD8 + T cells, but not limited thereto.
[0134] In one embodiment, the present invention relates to a T-cell engager comprising an antibody or an immunologically active fragment thereof that binds to ITGB2.
[0135] In one example, the T cell binder can be, for example, a bispecific T cell engager (BiTE). The BiTE is a type of artificial bispecific monoclonal antibody, which is a fusion protein consisting of two single-chain variable region fragments (scFv) derived from amino acid sequences of four different genes or different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells through the CD3 receptor, and the other binds to tumor cells through tumor-specific molecules. Similar to other bispecific antibodies, but different from ordinary monoclonal antibodies, BiTE forms a connection between T cells and tumor cells. It produces proteins such as perforin and granzymes to make T cells independent of the presence of MHC I or costimulatory molecules to exert cytotoxic activity on tumor cells. These proteins enter tumor cells and trigger cell apoptosis.
[0136] In one embodiment, the present invention relates to a pharmaceutical composition for preventing or treating cancer comprising the drug carrier, peptide-drug conjugate or antibody-drug conjugate of the present invention as an active ingredient.
[0137] In one embodiment, the present invention relates to an immunological anticancer agent comprising the drug carrier, peptide-drug conjugate or antibody-drug conjugate of the present invention as an effective ingredient.
[0138] In one example, the cancer may be a cancer mediated by M2 tumor-associated macrophages.
[0139] In one embodiment, the composition can be administered to a patient in which the expression of ITGB2 in M2 macrophages is upregulated compared with the expression in M0 macrophages and M1 macrophages.
[0140] In one example, the cancer can be selected from brain tumors, melanoma, myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, triple negative breast cancer (Triple Negative Breast Cancer, TNBC), lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube cancer, perianal cancer, endometrial cancer, vaginal cancer, vulvar cancer, Hodgkin's disease (Hodgkin's disease), esophageal cancer, lymph node cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, kidney or ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma and pituitary adenoma, and can be a cancer resistant to anticancer drugs.
[0141] The pharmaceutical composition of the present invention can be used as a single treatment method or used together with other common biological therapies, chemotherapy or radiotherapy. When such a combination therapy is implemented, cancer can be treated more effectively. When the present invention is used in the prevention and treatment of cancer, the chemotherapeutic agents that can be used together with the above-mentioned composition include cisplatin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, busulfan, nitrosourea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin C, etoposide, tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristine, vinblastine and methotrexate. Radiotherapy that can be used together with the composition of the present invention is X-ray irradiation and gamma ray irradiation.
[0142] In the present invention, the term "prevention" refers to all actions to inhibit or delay the occurrence, spread and recurrence of cancer by administering the composition of the present invention.
[0143] The therapeutically effective amount of the composition of the present invention may vary depending on a variety of factors, such as the method of administration, the target site, the patient's condition, etc. Therefore, when administered to the human body, the dosage should be determined by considering both safety and effectiveness. The amount used in humans can be deduced from the effective amount determined by animal experiments. Matters to be considered when determining the effective amount are described in, for example, Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EWMartin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
[0144] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" used in the present invention refers to an amount that is sufficient and does not cause side effects to treat a disease at a reasonable benefit / risk ratio that can be applied in medical treatment, and the effective dose level is determined based on factors including the patient's health status, the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the metabolic ratio, the treatment period, the drugs used in conjunction or simultaneously, and other factors well known in the medical field. The composition of the present invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with existing therapeutic agents. The key point is that after all the above factors are considered, the amount of the maximum effect is obtained with the minimum amount that does not cause side effects, which can be easily determined by a person of ordinary skill in the art to which the present invention belongs.
[0145] The pharmaceutical composition of the present invention may include a carrier, a diluent, an excipient or a combination of two or more of the carriers commonly used in biological preparations. The term "pharmaceutically acceptable" used in the present invention refers to a property that exhibits no toxicity to normal cells or humans exposed to the above-mentioned composition. The above-mentioned carrier is not particularly limited as long as it is suitable for delivering the composition into the body. For example, the compound recorded in Merck Index, 13th ed., Merck & Co. Inc., physiological saline, sterile water, Ringer's solution, buffered physiological saline, glucose solution, maltodextrin solution, glycerol, ethanol and a mixture of one or more of the above-mentioned components can be used, and other common additives such as antioxidants, buffers, sterilizers, etc. can also be added as needed. In addition, it can also be prepared into an injection dosage form, pills, capsules, granules or tablets such as an aqueous solution, a suspension, an emulsion, etc. by adding a diluent, a dispersant, a surfactant, a binder, and a lubricant. Furthermore, the drug can be preferably formulated according to each disease or component using an appropriate method in the technical field to which the present invention pertains or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0146] In one example, the pharmaceutical composition can be in one or more dosage forms selected from the group consisting of oral dosage forms, external preparations, suppositories, sterile injection solutions, and sprays.
[0147] The composition of the present invention may include a carrier, a diluent, an excipient or a combination of two or more of the carriers commonly used in biological preparations. Pharmaceutically acceptable carriers are not particularly limited as long as they are suitable for delivering the composition in vivo. For example, compounds recorded in Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol and one or more of the above components can be used, and antioxidants, buffers, sterilizers and other common additives can also be added as needed. In addition, it can also be prepared into injection dosage forms such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets by adding diluents, dispersants, surfactants, binders, and lubricants. Furthermore, it can be preferably prepared according to each disease or component using the appropriate method in the technical field of the present invention or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
[0148] The composition of the present invention may also include one or more active ingredients showing the same or similar functions. Relative to the total weight of the composition, the composition of the present invention comprises 0.0001 to 10 weight percent of the above protein, preferably, 0.001 to 1 weight percent of the above protein.
[0149] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, in which case, the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, starch syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, glucose, sorbitol, talc, etc. Preferably, relative to the above composition, the pharmaceutically acceptable additives of the present invention may be included in an amount of 0.1 to 90 parts by weight, but are not limited thereto.
[0150] The composition of the present invention can be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) or orally according to the intended method, and the dosage range can vary according to the patient's weight, age, sex, health status, diet, administration time, administration method, metabolic rate, and severity of the disease. The daily dosage of the composition of the present invention is 0.0001 mg / ml to 10 mg / ml, preferably 0.0001 mg / ml to 5 mg / ml, and more preferably, once a day or divided into several doses.
[0151] Liquid preparations for oral administration of the composition of the present invention include suspensions, internal solutions, emulsions, syrups, etc., which may contain, in addition to water and liquid paraffin, which are usually used as simple diluents, a variety of excipients, such as wetting agents, sweeteners, aromatics, preservatives, etc. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, oils, freeze-dried preparations, suppositories, etc.
[0152] In one embodiment, the present invention relates to a method for screening a substance that specifically delivers a drug to M2 tumor-associated macrophages, comprising the steps of treating a candidate substance to ITGB2; and screening the candidate substance that binds to ITGB2.
[0153] In one example, the above method can be used to screen candidate substances that specifically bind to CD18 in the extended active conformation.
[0154] In one embodiment, the present invention relates to a method for screening a patient responsive to an anticancer agent targeting M2 macrophages, comprising the step of confirming the expression level of ITGB2 in a separated sample.
[0155] In one example, the method may further include the following step: when the expression level of ITGB2 in M2 macrophages is higher than that in M0 macrophages and M1 macrophages, determining that the patient is responsive to an anticancer agent targeting M2 macrophages.
[0156] In one embodiment, the present invention relates to a solid cancer diagnostic marker comprising the ITGB2 gene or a protein expressed by the gene.
[0157] In one embodiment, the present invention relates to a composition for diagnosing solid cancer, comprising a preparation for measuring the expression amount of ITGB2 at the mRNA or protein level.
[0158] In one example, the agent measured at the mRNA level includes the nucleic acid sequence of the above-mentioned gene, a nucleic acid sequence complementary to the above-mentioned nucleic acid sequence, a primer pair, a probe, or a primer pair and a probe that specifically recognizes a fragment of the above-mentioned nucleic acid sequence and the complementary sequence, and the above-mentioned measurement can be performed by one or more methods selected from the group consisting of polymerase chain reaction, real-time reverse transcription polymerase chain reaction (Real-time RT-PCR), reverse transcription polymerase chain reaction, competitive polymerase chain reaction (Competitive RT-PCR), nuclease complementation analysis (RNase, S1 nuclease assay), in situ hybridization, nucleic acid microarray, Noble blot hybridization, DNA chip, multiplex polymerase chain reaction (multiplex PCR) or digital polymerase chain reaction (ddPCR).
[0159] In one example, the agent measured at the protein level can be an antibody, antibody fragment, nucleic acid aptamer, avimer (avidity multimer) or peptidomimetics that specifically recognizes the full-length protein of the above-mentioned gene or a fragment thereof, and the above-mentioned measurement can be performed by one or more methods selected from the group consisting of western blotting, enzyme linked immunosorbent assay (ELISA, enzyme linked immunosorbent assay), radioimmunoassay (RIA: Radioimmunoassay), radioimmunodiffusion, immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, fluorescence activated cell sorting (FACS), mass analysis and protein microarray.
[0160] The term "detecting" or "measuring" used in the present invention refers to quantifying the concentration of a subject to be detected or measured.
[0161] The term "primer" used in the present invention refers to a short nucleic acid sequence that can form a base pair with a template complementary to a nucleic acid sequence having a free 3-terminal hydroxyl group and function as a starting point for template chain replication. The primer can initiate DNA synthesis in the presence of a reagent for polymerization reaction (i.e., DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates at an appropriate buffer solution and temperature.
[0162] The term "probe" used in the present invention refers to a nucleic acid fragment such as RNA or DNA that can achieve specific binding with mRNA, ranging from a few bases to hundreds of bases, and can confirm the presence or absence of a specific mRNA due to being labeled. The probe can be prepared in the form of an oligonucleotide probe, a single-stranded DNA probe, a double-stranded DNA probe, an RNA probe, etc. In the present invention, hybridization is performed using a probe complementary to the above-mentioned ITGB2, and the expression level of the above-mentioned gene can be diagnosed by whether hybridization occurs. The selection of appropriate probes and hybridization conditions can be modified based on the content known in the technical field to which the present invention belongs, and there is no particular limitation in this regard in the present invention.
[0163] The primers or probes of the present invention can be synthesized chemically using the phosphoramidite solid phase support method or other well-known methods. Such nucleic acid sequences can also be deformed using many means known in the art to which the present invention belongs. Non-limiting examples of the above deformations include methylation, capping, substitution of one or more homologues of natural nucleotides, and deformation between nucleotides, for example, deformation to uncharged linkers (e.g., methyl phosphonates, phosphotriesters, aminophosphorylates, carbamates, etc.) or charged linkers (e.g., phosphorothioates, phosphorodithioates, etc.).
[0164] In the present invention, the appropriate conditions for hybridizing the probe to the cDNA molecule can be determined as a series of processes through optimization steps. In order to establish a protocol for use in the laboratory, these steps can be implemented by relevant practitioners in a series of processes. For example, conditions such as temperature, concentration of components, hybridization and washing time, buffer components and their pH, and ionic strength depend on various factors such as the length of the probe, GC content and target nucleotide sequence. Detailed conditions for hybridization can be confirmed in Joseph Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2001); and MLM Anderson, Nucleic Acid Hybridization, Springer-Verlag New York Inc. NY (1999). For example, the highly stringent conditions in the stringent conditions mentioned above refer to hybridization at 65°C in 0.5M sodium hydrogen phosphate (NaHPO4), 7% sodium dodecyl sulfate (SDS), and 1mM ethylenediaminetetraacetic acid (EDTA), and washing at 68°C in 0.1x standard saline citrate (SSC) / 0.1% SDS. In addition, the highly stringent conditions also refer to washing at 48°C in 6x SSC / 0.05% sodium pyrophosphate. The low stringent conditions refer to washing at 42°C in 0.2x SSC / 0.1% SDS, for example.
[0165] In one embodiment, the present invention relates to a method for predicting responsiveness or prognosis to an immunological anticancer agent targeting M2 macrophages, comprising the step of confirming the expression level of ITGB2 in a sample treated with the immunological anticancer agent of the present invention.
[0166] In one example, the method may further include the following step: when the expression level of ITGB2 protein in the sample decreases after the treatment with the immuno-anticancer agent, it is determined that the sample has a good responsiveness to the immuno-anticancer agent.
[0167] In one example, the sample can be blood, serum, plasma, amniotic fluid, saliva, ascites, bone marrow, tears, bile, lung lavage fluid, cerebrospinal fluid, pleural effusion, synovial fluid, lymph fluid, semen, urine, or a solution of protein extracted from tissue biopsy or cells.
[0168] In one embodiment, the present invention relates to a method for providing information required for diagnosis of cancer, comprising: a step of confirming the expression level of ITGB2 in a sample isolated from a subject; a step of comparing the expression level of ITGB2 with that of a control group; and a step of classifying subjects in which ITGB2 is overexpressed compared to the control group.
[0169] In one example, the method further includes the step of judging that the subject in which ITGB2 is overexpressed compared with the control group has a high possibility of having cancer.
[0170] In one embodiment, the present invention relates to a method for treating cancer, comprising the step of administering a pharmaceutically effective amount of the drug carrier of the present invention to a subject suffering from cancer.
[0171] In one example, the individual may be a patient in which the expression of ITGB2 in M2 macrophages is upregulated compared with the expression in M0 macrophages and M1 macrophages.
[0172] In one embodiment, the present invention relates to use of the drug carrier of the present invention in preparing a pharmaceutical composition for preventing and treating cancer.
[0173] The present invention will be described in more detail by the following examples. However, the following examples are only used to specify the contents of the present invention, and the present invention is not limited to these examples. DETAILED DESCRIPTION
[0175] Example 1. Synthesis of M2 tumor-associated macrophage (M2 TAM) targeting peptides
[0176] Melittin and TAMpep826 shown in Table 1 below were obtained by commissioning synthesis from GenScript (Piscataway, NJ, USA), and dissolved in D-PBS at a concentration of 5 mg / ml for use in subsequent experiments.
[0177] Table 1
[0178] name sequence Sequence number illustrate Melittin GIGAVLKVLTTGLPALISWIKRKRQQ 1 Melittin TAMpep826 VLTTGLPALISWIKRKRQQ 2 Peptide with the first 7 amino acids of melittin removed
[0179] Example 2. M2 TAM targeting analysis
[0180] 2-1. Confirmation of the affinity of melittin for M2 TAM
[0181] In order to confirm whether the melittin prepared in the above Example 1 specifically binds to M2 tumor-associated macrophages (M2 TAMs), human monocytic cell line THP-1 was differentiated into M0, M1 and M2 macrophages, and then treated with FITC-coupled melittin and confirmed by flow cytometry. Specifically, THP-1 cells were treated with 100 nM phorbol 12-myristate 13-acetate (PMA) at 37°C for 24 hours (M0 macrophages), and then the differentiated M0 macrophages were cultured with 100 nM LPS and 20 ng / ml IFN-γ at 37°C for 72 hours to differentiate into M1 macrophages (M1), and cultured with 20 ng / ml IL-4 and IL-13 at 37°C for 72 hours to differentiate into M2 macrophages (M2). After the differentiated cells were treated with 50 nM FITC-conjugated melittin for 1 hour, the cells were detected using BD FACSCantoII instruments (BD biosciences, San Jose, CA, USA) and analyzed using FlowJo software (BD biosciences).
[0182] The results showed that compared with M0 and M2 macrophages, the number of FITC-positive cells in M2 macrophages increased significantly ( Figure 1a and Figure 1b ). This confirmed that melittin preferentially binds to M2 macrophages.
[0183] 2-2. M2 TAM binding target protein recognition of melittin
[0184] In order to confirm which protein of M2 macrophages is related to the specific binding of melittin to M2 macrophages, biotin-conjugated melittin (melittin-biotin) was synthesized. 6After cells were differentiated into M0, M1 and M2 macrophages, the cells were collected with a scraper and washed by centrifugation (300×g, 5 minutes) and then the membrane protein of the macrophages was obtained using a membrane protein extraction kit (ThermoFisher scientific). After reacting with melittin-biotin (200 μg) bound to biotin at room temperature (20-24°C) for 1 hour, the protein bound to melittin was obtained using streptavidin resin (ThermoFisher). In order to remove salts, 100 μl of 100% ethanol, 0.1% formic acid and 80% CAN were added to a 18 Micro Spin-Column to prepare it, and after loading the sample on the prepared column, 50 μl of 0.1% formic acid was added to remove unnecessary substances. Then, 100 μl of 80% CAN was added to elute the peptide. After desalting, Speed-vac was used to dry the solution to completely remove it, and the solution was analyzed by LC-MS / MS using a UPLC-Exactive instrument (Thermo Fisher Scientific) under the conditions of Table 2 below. Data analysis was performed on proteins upregulated in M1 and M2 macrophages relative to M0 macrophages using MaxQuant and MPP (Mass Profiler Professional). For data analysis, Proteome Discoverer was used to analyze LC-MS / MS data at different time scales, and the database used the human database of Uniprot, and label-free quantification (LFQ, Label-Free Quantification) was performed. Modifications added oxidation (Oxidation) (M), carbamylation (Carbamyl) (N-term) and carbamidomethyl (Carbamidomethyl) (C), and the baseline option was none (none).
[0185] Table 2
[0186]
[0187] As a result, 53 proteins were up-regulated in M2 / M0 and 123 proteins were up-regulated in M1 / M0 ( Figure 2a ). Although more upregulated proteins interact with M1 macrophages than M2 macrophages, this is not the case for proteins present in the cell membrane. Among membrane proteins, ITGB2 was shown to be upregulated in M2 macrophages ( Figure 2b). In addition, cytokines such as IL-10 and CXCL10, which are known markers of M1 macrophages, were upregulated in M1 macrophages (Figure 2v). In addition, although proteins that were upregulated in M2 compared to M1 were confirmed, only ITGB2 was confirmed to be upregulated in M2 macrophages among membrane proteins ( Figure 2d ). This confirmed that melittin interacts and binds to the membrane protein ITGB2 of M2 macrophages.
[0188] 2-3. M2 TAM binding target protein recognition by TAMpep826
[0189] In the same manner as in Example 2-2, cell membrane proteins extracted from M0, M1, and M2 macrophages were reacted with TAMpep826-biotin, and the target protein was confirmed by LC-MS / MS proteomics.
[0190] As a result, among the cell membrane proteins, ITGB2 was shown to be expressed at a higher level in M2 macrophages compared to M0 and M1 macrophages ( Figure 4 ), TAMpep826 was identified as a binding target protein of M2 macrophages.
[0191] Example 3. Confirmation of ITGB2 expression in M2 macrophages
[0192] 3-1. Confirmation of ITGB2 mRNA expression
[0193] In order to evaluate the mRNA expression level of ITGB2 in M0, M1, M2 macrophages and TAMs, real-time polymerase chain reaction was performed. Specifically, RNA was extracted from cells differentiated into M0, M1 or M2 macrophages using the easy-BLUE total RNA Extraction Kit (iNtRON), and cDNA was synthesized using CycleScript-Reverse Transcriptase (Bioneer). Primers for Actin or ITGB2 genes (Table 3) were used and the expression of Figure 5 Real-time polymerase chain reaction (real-time PCR) (CFX96, Bio-rad) was performed under the conditions to compare and analyze the expression level of each gene relative to Actin by relative quantification.
[0194] Table 3
[0195]
[0196] The results showed that the mRNA expression of ITGB2 was significantly increased in M2 macrophages and TAMs compared with M0 and M1 macrophages ( Figure 6 ).
[0197] 3-2. Confirmation of ITGB2 protein expression
[0198] Western blot analysis was performed to evaluate the protein expression level of ITGB2 in M0, M1, M2 macrophages and TAMs. Specifically, proteins were extracted from cells differentiated into M0, M1 and M2 macrophages using Proprep solution (iNtRON) and transferred to the membrane using electrophoresis. The membrane was blocked by soaking in 5% bovine serum albumin (BSA), treated with primary antibody (ITGB2) at 4°C for 24 hours, treated with secondary antibody at room temperature for 1 hour, and treated with D-Plus TM ECL Pico System (Dongren LS Co., Ltd.) and then used Davinch-Chemi TM The protein bands were photographed using an imaging system (Intoxia).
[0199] The results showed that the protein expression of ITGB2 was significantly increased in M2 macrophages and TAMs compared with M0 and M1 macrophages ( Figure 7 ).
[0200] 3-3. Confirmation of ITGB2 protein expression by immunofluorescence
[0201] In order to evaluate the protein expression level of ITGB2 in M0, M1, M2 macrophages and TAMs, immunofluorescence analysis was performed. Specifically, each cell differentiated into M0, M1 and M2 macrophages was fixed with 4% formalin, washed with PBS and immersed in 5% BSA for blocking, and then treated with primary antibody (ITGB2) at 4°C for 24 hours and secondary antibody at room temperature for 2 hours. After DAPI-stained cells were counted (mounting), fluorescent photos were taken using LSM800 (Zeiss).
[0202] The results showed that the expression level of ITGB2 protein was higher in M2 macrophages and TAMs than in M0 and M1 macrophages ( Figure 8 ).
[0203] Example 4. Confirmation of the interaction between M2 TAM targeting peptide and ITGB2
[0204] 4-1. Confirmation of ITGB2 expression on the cell membrane of M2 macrophages
[0205] In order to confirm whether ITGB2 is expressed in the cell membrane of M2 macrophages, cell membrane proteins and cytosol proteins were isolated and extracted from M2 macrophages, respectively, and then reacted with biotinylated TAMpep826 and evaluated by Western blot analysis. The results showed that ITGB2 protein was expressed in the cell membrane of M2 macrophages ( Fig. 9 ).
[0206] 4-2. Confirmation of the interaction between TAMpep826 and ITGB2
[0207] In order to confirm whether TAMpep826 interacts with ITGB2 in M2 macrophages, the expression of ITGB2 was evaluated by a competitive reaction between TAMpep826 and biotinylated TAMpep826. Specifically, cells differentiated into M2 macrophages were collected using a scraper and washed by centrifugation (300×g, 5 minutes), and then the cell membrane proteins of macrophages were obtained using a cell membrane protein extraction kit (Thermo Fisher Scientific). TAMpep826 or scramble peptide was pretreated for 1 hour at different concentrations (0.001μg, 0.01μg, 0.1μg, 1μg and 10μg), and then reacted with biotin-bound TAMpep826 (200μg) at room temperature (20-24°C) for 1 hour using Dynabeads. TM M-280 streptavidin (Thermo Fisher Scientific) was used to obtain proteins bound to TAMpep826. Proteins were analyzed by Western blotting to confirm the expression of ITGB2.
[0208] The results showed that when the scrambled peptide was pretreated, the expression of ITGB2 bound to biotinylated TAMpep826 was not affected. On the contrary, when TAMpep826 was pretreated, the expression of ITGB2 was inhibited as the concentration increased ( Fig.10 ). This confirmed that TAMpep826 interacts with ITGB2 in the cell membrane of M2 macrophages.
[0209] 4-3. Confirmation of the interaction between TAMpep826 and ITGB2 by immunofluorescence
[0210] In order to confirm whether ITGB2 and TAMpep826 co-localize in the cell membrane of M2 macrophages, immunofluorescence analysis was performed using TAMpep826 conjugated with FITC. The results showed that TAMpep826 and ITGB2 were concentrated in the cell membrane of M2 macrophages ( Fig.11 ).
[0211] 4-4. Confirmation of the binding site between TB511 and ITGB2
[0212] Based on the sequence of the cysteine-rich portion of CD18 (ITGB2) (uniport_p05107 , Cystein-rich tandem repeats region: 449-617), and the tertiary structure was constructed using the trRosetta algorithm (https: / / yanglab.nankai.edu.cn / trRosetta / ). Then, the docking simulation of TB511 and CD18 was performed using the CD18 PDB file produced by trRosetta and the amino acid sequence of TB511, using the CABS-dock server (http: / / biocomp.chem.uw.edu.pl / CABSdock / ). Among the 10 models obtained from the docking simulation results, the representative model was selected based on the alanine substitution results of the TB511 sequence ( Fig.12 ).
[0213] As a result, it was predicted that LEU (6) of TB511 would bind to the LEU (528), THR (538), LEU (556), CYS (557) and PHE (558) sites of CD18, and it was predicted that TRP (12) of TB511 would bind to GLU (466), ILE (469), CYS (470) and ARG (471) of CD18. Furthermore, when LEU (6) and TRP (12) of TB511 were replaced with alanine to simulate binding with CD18, it was shown that both sites did not bind to any sequence of CD18. Therefore, it was predicted that LEU (6) and TRP (12) of TB511 were the core parts of the docking between TB511 and CD18, and it could be predicted that TB511 would bind to sites 466 to 565 of CD18 ( Fig.13 ).
[0214] Example 5. Synthesis of ITGB2 binding moieties
[0215] 5-1. Synthesis of ITGB2-binding PDC (peptide-drug conjugate)
[0216] After commissioning synthesis from GenScript (Piscataway, New Jersey, USA), the bee venom peptide-dKLA and TB511 peptides shown in Table 4 were obtained and dissolved in D-PBS at a concentration of 5 mg / ml for use in subsequent experiments. dKLA is linked via an amide bond between peptides. In order to minimize the interaction and folding between bee venom peptide or TAMpep826 and dKLA, a linker consisting of 4 glycines and 1 serine is set in the middle to distinguish the two ends. In order to minimize in vivo decomposition, KLA uses the D-isomer instead of the L-isomer. Furthermore, in order to prepare M-DM1, maleimide-modified bee venom peptide (GenScript, Beijing, China) (100 μM, 1 mL, 0.1 mmoL) dissolved in 25 mM sodium borate buffer (25 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0) was added with DM1 (Mertansine) (MedChem Express, Princeton) (1.1 equivalents, 10 mM in DMF) and DMF (dimethylformamide) and reacted at 37° C. for 1 hour, and the resultant was filtered three times by ultrafiltration in Dulbecco's phosphate buffered saline (DPBS; Welgene), thereby preparing PDC by binding DM1 to the N-terminus of maleimide-modified bee venom peptide M, and it was named M-DM1. The prepared M-DM1 was injected into a reverse phase high performance liquid chromatograph (HPLC) at a flow rate of 5 μL and 0.5 mL / min in a Poroshell 120C18 column (2.7 μm, 3×50 mm, Agilent, Santa Clara, CA, USA) to analyze the properties.
[0217] Table 4
[0218]
[0219]
[0220] 5-2-1. Preparation of ADCs of anti-CD18 antibody and DM1
[0221] In order to prepare an antibody that specifically binds to the active conformation of CD18, which is one of the macrophage-1 antigens (Mac-1), in M2 TAMs ( Fig.14), collect the culture fluid of hybridoma (MM18 / 2.a.8) cells secreting anti-CD18 antibodies, centrifuge at 2500rpm at 4°C for 10 minutes to obtain the supernatant, and then purify it by protein G-agarose column chromatography. The antibody solution is slowly passed through a protein G-agarose column (Pharmacia, Sweden) pre-equilibrated with PBS, and the column is connected to a peristaltic pump and washed thoroughly with PBS. After washing, the antibody is eluted with 0.2M glycin-HCl (pH 2.7). In this case, the eluate is buffered in a test tube containing 1M Tris (pH 9.0) prepared in advance. The antibody is used after dialysis in PBS. Using a BCA protein analysis kit (BCA TM Protein Assay Kit, Pierce) was used to measure the amount of purified antibody, and the binding ability of the antibody was confirmed by flow cytometry analysis. After the buffer was replaced with PBS (pH 7.4) for anti-CD18 antibody, SMCC-DM1 (mertansine, 120 μM) (MedChemExpress) dissolved in dimethyl sulfoxide (DMSO) was mixed with anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:18 and reacted at room temperature for 4 to 20 hours. In order to remove unreacted DM1, PBS (pH 7.4) was used to replace the buffer for anti-CD18-DM1 using a 10KDa cutoff centrifugal filter, and then filtered using a 0.2 μm syringe filter. The amount of DM1 (252 nM) bound to the anti-CD18 antibody (280 nM) was measured by UV-Vis spectroscopy to calculate the ratio of DM1 to the anti-CD18 antibody (DAR), and the DAR value was 5.8. The ADC prepared in this way in which the anti-CD18 antibody and DM1 were bound was named CD18-DM1.
[0222] 5-2-2. Preparation of ADCs of anti-CD18 antibodies and MMAE (monomethyl auristatin E)
[0223] After the anti-CD18 antibody purified in the above example was buffer exchanged with PBS (pH 7.4), in order to partially reduce the disulfide bond of the CD18 antibody, 1 mM DTT (66.7 μM) was mixed with the anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:10, reacted at 37°C for 1 to 2 hours, and then the buffer was exchanged with PBS (pH 7.4). 10 mM Suo-Val-Cit-PAB-MMAE (MedChemExpress) was mixed with the partially reduced anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:20 to 1:40, reacted at 4°C for 12 hours, and then the buffer was exchanged with PBS (pH 7.4). The amount of vc-MMAE (248 nM) bound to anti-CD18 antibody (280 nM) was measured by UV-Vis spectrometer to calculate the ratio of vc-MMAE to anti-CD18 antibody (Drug antibody ratio, DAR), and the DAR value was shown to be 2.8 to 5.4. The ADC in which the anti-CD18 antibody prepared in this way is bound to MMAE is named CD18-MMAE.
[0224] Example 6. Confirmation of ITGB2 binding to M2 TAM binding of PDC
[0225] In order to confirm the binding force between ITGB2 and melittin-dKLA, the ITGB2 protein was fixed on a golden thin film sensor chip, and the ITGB2 antibody and melittin-dKLA as a positive control group were flowed through to measure the reflected light, and then surface plasmon resonance (SPR) analysis was performed. Specifically, after ITGB2 was fixed on the surface of the sensor chip, it was immobilized using amine coupling under the conditions of Table 5 below ( Fig.15 Then, various concentrations of ITGB2 antibody and melittin-dKLA were passed through the ITGB2-coated sensor to observe the association and dissociation intervals, and the intermolecular binding rate constant (kinetic constant (kinetic prarmeter)) was calculated from the sensorgram using the intermolecular binding rate constant analysis (kinetic evaluation (kinetic evoluation)) conditions in Table 6 below.
[0226] Table 5
[0227]
[0228] Table 62) Kinetic evaluation
[0229]
[0230] As a result, the equilibrium dissociation constant (KD) obtained by dividing the dissociation rate constant (kd) of the binding force between two molecules of the ITGB2 antibody as a positive control group by the association rate constant (ka) was 1.14. -8 The equilibrium dissociation constant of melittin-dKLA is shown to be 7.86 -8 ( Fig.16 and Fig.17 ). Therefore, it was confirmed that melittin-dKLA has binding ability with ITGB2.
[0231] Example 7. Confirmation of the apoptotic effect of ITGB2 on M2 TAM cells via PDC
[0232] 7-1. Preparation of ITGB2 expression inhibition cell model
[0233] As a cell model for confirming whether ITGB2 induces apoptosis in M2 macrophages, a cell model for inhibiting ITGB2 expression in M2 macrophages was prepared using Crispr / cas9. Specifically, cells differentiated into M2 macrophages were cultured in Opti-MEM medium. Crispr / cas9 is a cell model for inducing apoptosis in M2 macrophages by inserting CRISPRMAX TM Cas9 protein V2 (Thermo Fisher Scientific) and gRNA (Genscript; ITGB2; Table 7) of the Reagentkit (Thermo Fisher Scientific) and Cas9 Plus TM Reagent (Thermo Fisher Scientific) was mixed together and CRISPRMAX TM The reagent was diluted in Opti-MEM medium and mixed to react for 5-10 minutes, then added to the cells differentiated into M2 macrophages and cultured at 37° C. for 2-3 days. Then, the mRNA expression level of ITGB2 was confirmed.
[0234] Table 7
[0235]
[0236] The results showed that the expression of ITGB2 in M2 macrophages injected with ITGB2 sgRNA was significantly reduced compared with the control group ( Fig.18 ).
[0237] 7-2. Confirmation of M2 TAM cell apoptosis by ITGB2 via melittin-dKLA
[0238] In order to confirm whether bee venom peptide-dKLA binds to ITGB2 in M2 macrophages to induce apoptosis, bee venom peptide-dKLA (1 μM) was treated for 24 hours to M2 macrophages in which ITGB2 expression was inhibited by Crispr / cas9 prepared in Example 7-1 above, and the cell survival rate was analyzed by CCK-8 analysis. Specifically, bee venom peptide-dKLA (1 μM) was reacted to ITGB2 knockdown macrophages prepared in Example 7-1 above for 1 hour. After the reaction, the culture medium was replaced and cultured at 37°C for 24 hours. In order to confirm the cell viability, 1 / 10 of the CCK-8 reagent (EnzoLife Sciences) was placed in the culture medium and reacted at 37°C for 3 hours. The absorbance was measured at a wavelength of 450nM using a microplate reader (Molecular Devices).
[0239] As a result, the cell survival rate of M2 macrophages in the control group was significantly reduced by melittin-dKLA, but the reduction of cell survival rate by melittin-dKLA was suppressed in M2 macrophages with ITGB2 knockdown ( Fig.19 ). Therefore, it was confirmed that melittin-dKLA induces apoptosis of M2 macrophages by specifically binding to ITGB2 of M2 macrophages.
[0240] 7-3. Confirmation of TB511-induced apoptosis of M2 TAM cells via ITGB2
[0241] In order to confirm whether TB511 (TAMpep826-dKLA) induces apoptosis in M2 macrophages through ITGB2, the M2 macrophages in which ITGB2 expression was inhibited by Crispr / cas9 prepared in Example 7-1 were reacted with TB511. The results showed that M2 macrophages showed about 50% cell viability by TB511, but in cells in which ITGB2 expression was inhibited, cell viability was significantly increased ( Fig. 20 ).
[0242] 7-4. Confirmation of reduction of apoptosis induction in TB511 cells by ITGB2 antibody
[0243] In order to determine whether TB511 induces apoptosis in M2 macrophages through ITGB2, the M2 macrophages prepared in the above Example 7-1 for inhibiting ITGB2 expression were pretreated with anti-ITGB2 antibody (polyclonal rabbit anti-human ITGB2 / CD18 antibody) (LS-C312785; LS Bio) (1 μg) for 1 hour and reacted with TB511 (1 μM) for 1 hour. Then, the induction of apoptosis was confirmed by cell viability analysis using CCK-8 analysis, the protein expression of caspase-3, a cell apoptosis marker, was confirmed by Western blotting analysis, the gene expression of caspase-3, caspase-8, and caspase-9 was confirmed by real-time polymerase chain reaction, and the induction of caspase-3 protein expression was confirmed by immunofluorescence.
[0244] As a result, the cell viability of M2 macrophages was not affected by ITGB2 antibody, but was significantly reduced by TB511. In contrast, in M2 macrophages pretreated with ITGB2 antibody, the cell viability was significantly increased by TB511 ( Fig.21 ). In addition, TB511 significantly increased the expression of caspase-3 in M2 macrophages, whereas TB511 significantly reduced the expression of caspase-3 in M2 macrophages pretreated with ITGB2 antibodies ( Fig.21 ). In addition, the expression of caspase-3, caspase-8, and caspase-9 in M2 macrophages was significantly increased by TB511. On the contrary, the expression of caspase-3, caspase-8, and caspase-9 in M2 macrophages pretreated with ITGB2 antibody was significantly reduced by TB511 ( Fig.21 ). TB511 significantly increased the expression of caspase-3 in M2 macrophages. Conversely, TB511 reduced the expression of caspase-3 in M2 macrophages pretreated with ITGB2 antibodies ( Fig.21 ). In addition, the results of confirming that TB511 targets mitochondria showed that the coexistence of mitochondria and TB511 decreased in M2 macrophages pretreated with ITGB2 antibodies compared with cells not pretreated with ITGB2 ( Fig.21 ).
[0245] Example 8. Confirmation of the efficacy of PDCs in three-dimensional cancer organoids
[0246] 8-1. Confirmation of the effect of TB511 in breast cancer 3D organoids
[0247] In order to correct the critical point in vitro and then replace it in vivo, a three-dimensional organoid was prepared to simulate the cancer microenvironment (TME) of breast cancer and confirm the effect of TB511 on it. Specifically, after mixing matrigel at a concentration of 3% with RPMI-1640 culture medium, MDA-MB-231 human breast cancer cells, cancer-associated fibroblasts (CAFs) and Nuclight Lentivirus Reagents (Sartorius) were used to count THP-1 cells prepared to express GFP, and then 200 μl was dispensed into a 96-well u-bottom 3-D culture plate at a ratio of 5:1:1. After culture, the cells were collected by centrifugation at 1200 rpm for 3 minutes, and then cultured in a 37°C incubator for 48 hours to form spheroids. Starting from the second day after spheroid formation, TB511 was treated at concentrations of 1 μM, 2 μM, 4 μM, and 8 μM every three days, and images were taken using a fluorescence microscope. After taking bright-field images, the diameter of the particles was measured by a measurement method to measure the spheroid area. In addition, after measuring 3 diameters for each sphere using open source, the size of the average tumor rotation ellipse diameter was analyzed by ImageJ (software version 1.47m), and after taking bright field images (20X), the sphere size was analyzed by ImageJ (software version 1.47m) after measuring 3 average tumor rotation ellipsoid diameters for each sphere. At the same time, after fixing the spheres on the 10th day of drug treatment, they were reacted with antibodies to ki-67 (abcam), a tumor growth factor, for immunofluorescence staining (control staining: DAPI). In the case of THP-1, no additional staining was performed, and the GFP fluorescence expressed in the cells was photographed using a confocal microscope and the number of cells expressing fluorescence was measured.
[0248] The results showed that the size of the spheres in the group without drug treatment gradually increased over time, and THP-1 cells, which are monocytes, differentiated into TAMs through cancer cells and TME when cancer cells and CAFs were co-cultured, thereby promoting tumor growth. In contrast, in the group treated with TB511, it was confirmed that the size of the spheres decreased in a concentration-dependent manner starting from a concentration of 1 μM on day 10 ( Fig. 22 ), compared with the drug-free group, the number of THP-1 cells expressing GFP fluorescence was significantly reduced in a concentration-dependent manner (*** p<0.001)( Fig.23 ). Thus, it was confirmed that TB511, an ITGB2-binding PDC, induces apoptosis of MDA-MB-231 human breast cancer cells by selectively binding to THP-1 cells.
[0249] 8-2. Confirmation of the effect of TB511 in lung cancer 3D organoids
[0250] After A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to prepare lung cancer three-dimensional spheroids, TB511 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and the effect was analyzed by the same method as in Example 8-1. When preparing spheroids, three-dimensional spheroids were prepared using cancer cells alone or only cancer cells + CAF cells were mixed to compare the size of the spheroids.
[0251] The results showed that the size of spheres formed with A549+CAF+THP-1 cells increased significantly compared with the case of spheres formed with A549 cells alone or A549+CAF cells alone. In addition, the size of spheres in the TB511-treated group decreased significantly depending on the TB511 concentration compared with the group not treated with TB511 ( *** p<0.001)( Fig.24 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 was also reduced in a concentration-dependent manner ( *** p<0.001)( Fig.25 ).
[0252] 8-3. Confirmation of the effect of M-DM1 in lung cancer 3D organoids
[0253] In order to confirm the efficacy of M-DM1 (Mel-DM1) against lung cancer, A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to prepare lung cancer 3D spheroids, and then M-DM1 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.
[0254] The results showed that the size of spheres in the M-DM1 treated group decreased in a concentration-dependent manner compared with the M-DM1 untreated group ( *** p<0.001)( Fig.26 ).
[0255] Example 9. Confirmation of the efficacy of PDC in three-dimensional cancer organoids resistant to anticancer agents
[0256] 9-1. Confirmation of the effect of TB511 in three-dimensional organoids of lung cancer resistant to anticancer drugs
[0257] In order to confirm the efficacy of TB511 against carboplatin-resistant lung cancer, carboplatin-resistant A549 cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then TB511 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.
[0258] The results showed that the size of spheres formed by A549+CAF+THP-1 cells was significantly increased compared with the case of spheres formed by A549 resistant cells alone or A549+CAF cells alone. The size of spheres in the TB511 treated group was significantly reduced in a TB511 concentration-dependent manner compared with the group not treated with TB511 ( *** p<0.001)( Fig. 27 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells in the TB511-treated group was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 also decreased significantly starting from a concentration of 2μM ( *** p<0.001)( Fig.28 ).
[0259] 9-2. Confirmation of the effect of TB511 in three-dimensional organoids of prostate cancer resistant to anticancer drugs
[0260] In order to confirm the efficacy of TB511 against docetaxel-resistant prostate cancer, docetaxel-resistant PC3 prostate cancer cells, CAFs and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then TB511 was treated at a concentration of 1 μM, 2 μM or 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.
[0261] The results showed that the size of spheroids formed by PC3+CAF+THP-1 cells was significantly increased compared with the case of spheroids formed by PC3 resistant cells alone or PC3+CAF cells alone. Compared with the group not treated with TB511, the size of spheroids in the group treated with TB511 was significantly reduced in a TB511 concentration-dependent manner ( *** p<0.001)( Fig.29 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells in the TB511-treated group was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 also showed a decreasing trend ( ** p<0.01, *** p<0.001)( Fig.30 ).
[0262] Example 10. Confirmation of ADC efficacy in three-dimensional cancer organoids
[0263] 10-1. Confirmation of the effect of ADC in 3D breast cancer organoids
[0264] In order to confirm the efficacy of ITGB2-binding ADC against breast cancer, MDA-MB-231 human breast cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheroids, and CD18-DM1 or CD18-MMAE, which are ADCs of the present invention, were treated at concentrations of 10 μg and 20 μg, respectively, and the effects were analyzed by the same method as in Example 8-1.
[0265] The results showed that the size of breast cancer spheres in the group without ADC treatment gradually increased over time, but the size of spheres in the group with ADC treatment decreased from the 8th day ( Fig.31 and Fig.32 ). In addition, the number of GFP-positive THP-1 cells increased strongly in the group not treated with ADC, but decreased in a concentration-dependent manner in the group treated with CD18-DM1 or CD18-MMAE ( *** p<0.001)( Fig.31 and Fig.32 ).
[0266] 10-2. Confirmation of the effect of ADC in lung cancer 3D organoids
[0267] In order to confirm the efficacy of ADC against lung cancer, A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheroids, and CD18-DM1 or CD18-MMAE, which are ADCs of the present invention, were treated at a concentration of 10 μg, and the effects were analyzed by the same method as in Example 8-1.
[0268] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. On the contrary, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE began to decrease from the 8th day ( Fig.33 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 8th day after drug treatment showed that THP-1 cells increased strongly in the group not treated with ADC, while in contrast, they decreased significantly in the group treated with ADC ( *** p<0.001)( Fig.34 ).
[0269] Example 11. Confirmation of ADC efficacy in anticancer agent-resistant three-dimensional cancer organoids
[0270] 11-1. Confirmation of the effect of ADC in three-dimensional organoids of lung cancer resistant to anticancer drugs
[0271] In order to confirm the efficacy of ADC against carboplatin-resistant lung cancer, carboplatin-resistant A549 cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then CD18-DM1 or CD18-MMAE were treated at a concentration of 10 μg, respectively, and the effects were analyzed by the same method as in Example 8-1.
[0272] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. On the contrary, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE began to decrease from the 8th day ( Fig.35 ). In addition, the results of fluorescent staining of the spheres on the 8th day after drug treatment to confirm the results of related markers showed that the number of THP-1 cells in the groups treated with CD18-DM1 or CD18-MMAE was significantly reduced compared with the groups not treated with ADC, and the tumor growth factor ki-67 was also reduced ( *** p<0.001)( Fig.36 ).
[0273] 11-2. Confirmation of the effect of ADC in three-dimensional organoids of prostate cancer resistant to anticancer drugs
[0274] In order to confirm the efficacy of ADC against docetaxel-resistant prostate cancer, docetaxel-resistant PC3 prostate cancer cells, CAF and THP-1 cells were mixed to form three-dimensional spheres by the method of Example 8-1 above, and then CD18-DM1 or CD18-MMAE were treated at a concentration of 10 μg respectively and their effects were analyzed by the same method as in Example 8-1 above.
[0275] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. In contrast, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE decreased from day 8 ( Fig.37 ). In addition, the results of immunofluorescence staining of the spheroids to analyze related markers on the 8th day after drug treatment showed that the fluorescence in the group without ADC treatment increased strongly. On the contrary, the number of THP-1 cells in the group treated with CD18-DM1 or CD18-MMAE decreased significantly, and the tumor growth factor ki-67 also decreased ( *** p<0.001)( Fig.38 ).
Claims
1. A drug carrier, characterized in that It comprises an ITGB2 binding portion and a drug bound thereto.
2. The drug carrier according to claim 1, characterized in that The ITGB2 binding portion is a small molecule, virus, antibody, antibody fragment, nucleic acid aptamer, hormone, cytokine, chemokine, ligand, a peptide that is a part of the region of a cytokine, or a peptide that is a part of the region of a ligand that specifically binds to ITGB2.
3. The drug carrier according to claim 1, characterized in that The ITGB2 binding moiety specifically binds to the extended active conformation of CD18.
4. The drug carrier according to claim 1, characterized in that ITGB2 comprises the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO:
8.
5. The drug carrier according to claim 1, characterized in that The ITGB2 binding portion binds to amino acids 449 to 617 of ITGB2.
6. The drug carrier according to claim 5, characterized in that The ITGB2 binding portion comprises the amino acid sequence of sequence 1 or sequence 2.
7. The drug carrier according to claim 5, characterized in that An amino acid sequence comprising sequence 5 or sequence 6.
8. The drug carrier according to claim 1, characterized in that The ITGB2 binding portion binds to amino acids 449 to 617 of ITGB2.
9. The drug carrier according to claim 1, characterized in that The ITGB2 binding portion binds to amino acids 732 to 748, amino acids 504 to 508, amino acids 534 to 546, amino acids 449 to 617, or amino acids 23 to 700 of ITGB2.
10. The drug carrier according to claim 1, characterized in that The ITGB2 binding moiety comprises an anti-CD18 antibody or an immunologically active fragment thereof.
11. The drug carrier according to claim 10, characterized in that The immunologically active fragment is any one selected from the group consisting of Fab, Fd, Fab', dAb, F(ab'), F(ab')2, scFv, Fv, single-chain antibody, Fv dimer, complementarity determining region fragment, humanized antibody, chimeric antibody and bispecific antibody.
12. The drug carrier according to claim 1, characterized in that The drug is a chemical compound, RNA, DNA, antibody, effector, prodrug, toxin, peptide or radionuclide.
13. The drug carrier according to claim 1, characterized in that The drug is an immunogenic apoptosis inducer, a pro-apoptotic peptide, a microtubule structure formation inhibitor, a mitotic inhibitor, a topoisomerase inhibitor, a DNA intercalator, a toxin, or an anticancer agent.
14. The drug carrier according to claim 13, characterized in that The pro-apoptotic peptide is selected from the group consisting of KLA, α-defensin-1, BMAP-28, Brevenin-2R, Buforin IIb, cecropin A-magnacin 2, cecropin A, cecropin B, chrysophsin-1, D-K6L9, Gomesin, lactoferrin peptide B, LLL27, LTX-315, magainin 2, magainin II-beast antimicrobial peptide conjugate, parrot toxin and a combination thereof.
15. The drug carrier according to claim 13, characterized in that The immunogenic apoptosis inducer is selected from the group consisting of anthracycline anticancer agents, taxane anticancer agents, anti-EGFR antibodies, BK channel agonists, bortezomib, cardiac glycosides, cyclophosphamide anticancer agents, GADD34 / PP1 inhibitors, LV-tSMAC, measles virus, bleomycin, mitoxantrone, oxaliplatin and combinations thereof.
16. The drug carrier according to claim 13, characterized in that The anticancer agent is selected from 7-ethyl-10-hydroxycamptothecin, daunorubicin, doxorubicin, epirubicin, idarubicin, pixantrone, sabarubicin, valrubicin, paclitaxel, docetaxel, mechlorethamine, chlorambucil, phenylalanine, mechlorethamine, cyclophosphamide, ifosfamide, carmustine, lomustine, streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, actinomycin D, plicamycin, mitomycin C, vincristine, vinblastine, teniposide, topotecan, irinotecan, uramustine, melphalan, bendamustine, dacarbazine, temozolomide, hexamethasone, The invention is selected from the group consisting of duocarmycin, nedaplatin, oxaliplatin, satraplatin, triplatinium tetranitrate, 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cilastatin, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, mercaptoguanine, etoposide, mitoxantrone, ixabepilone, vindesine sulfate, isovinablastine, estramustine, maytansine, maytansine DM1, maytansine DM4, dolastatin, auristatin E, auristatin F, monomethyl auristatin E, monomethyl auristatin F and their derivatives.
17. The drug carrier according to claim 1, characterized in that The drug is delivered specifically to M2 tumor-associated macrophages.
18. A peptide-drug conjugate, characterized in that: The invention comprises an ITGB2 binding part containing melittin, its variants or their analogs and a drug binding thereto.
19. The peptide-drug conjugate according to claim 18, characterized in that Binds to amino acids 466 to 565 of ITGB2.
20. The peptide-drug conjugate according to claim 18, characterized in that Binds to LEU(528), THR(538), LEU(556), CYS(557), PHE(558), GLU(466), ILE(469), CYS(470) or ARG(471) of ITGB2.
21. An antibody-drug conjugate, characterized in that: The invention comprises an antibody or an immunologically active fragment thereof that binds to ITGB2 and a drug that binds to the antibody.
22. The antibody-drug conjugate according to claim 21, characterized in that Binds to an epitope comprising amino acids 732 to 748, an epitope comprising amino acids 504 to 508, an epitope comprising amino acids 534 to 546, an epitope comprising amino acids 449 to 617, or an epitope comprising amino acids 23 to 700 of ITGB2.
23. The antibody-drug conjugate according to claim 21, characterized in that: Antibody-drug conjugate linkers are also included.
24. The antibody-drug conjugate according to claim 23, characterized in that The antibody-drug conjugate linker is 6-maleimidocaproyl, maleimidopropionyl, valine-citrulline, alanine-phenylalanine, p-aminobenzyloxycarbonyl, N-succinimidyl 4-(2-pyridylthio) pentanoate, N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline-p-aminobenzyloxycarbonyl or N-succinimidyl (4-iodoacetyl) aminobenzoate.
25. A pharmaceutical composition for preventing or treating cancer, characterized in that: The composition comprises the drug carrier according to claim 1, the peptide-drug conjugate according to claim 18 or the antibody-drug conjugate according to claim 21 as an active ingredient.
26. The pharmaceutical composition for preventing or treating cancer according to claim 25, characterized in that: The drug is administered to patients whose expression of ITGB2 in M2 macrophages is upregulated compared with that in M0 macrophages and M1 macrophages.
27. A method for screening a substance that specifically delivers a drug to M2 tumor-associated macrophages, characterized in that: include: Steps for treating candidate substances to ITGB2; as well as Steps for screening candidate substances that bind to ITGB2.
28. The method for screening a substance that specifically delivers a drug to M2 tumor-associated macrophages according to claim 27, characterized in that: Screening for candidate substances that specifically bind to CD18 in the extended active conformation.
29. A method for screening patients responsive to an anticancer agent targeting M2 macrophages, characterized in that: The method includes the step of confirming the expression level of ITGB2 in the separated sample.
30. The method for screening patients responsive to an anticancer agent targeting M2 macrophages according to claim 29, characterized in that: When the expression level of ITGB2 in M2 macrophages is higher than the expression levels of ITGB2 in M0 macrophages and M1 macrophages, the patient is judged to be responsive to an anticancer agent targeting M2 macrophages.
31. A method for treating cancer, characterized in that: The method comprises the step of administering a pharmaceutically effective amount of the drug carrier of claim 1, the peptide-drug conjugate of claim 18 or the antibody-drug conjugate of claim 21 to an individual suffering from cancer.
32. Use of a drug carrier in preparing a pharmaceutical composition for preventing and treating cancer.
